PremiumThe FlyAcurx granted new patent for DNA Polymerase IIIC Inhibitors Acurx files to sell 8.4M shares of common stock for holders Optimistic Buy Rating for Acurx Pharmaceuticals Amidst Financial Challenges and Promising Ibezapolstat Data PremiumThe FlyAcurx reports Q4 EPS (16c) vs. (37c) last year Acurx to sell 2.745M shares at 40c in registered direct offering Biotech Alert: Searches spiking for these stocks today PremiumThe FlyAcurx receives positive EMA guidance for ibezapolstat Phase 3 program Acurx updates Phase 3 readiness for ibezapolstat in C. difficile Infection Acurx board approves Bitcoin as treasury reserve asset